Bora Pharmaceuticals (“Bora” or “Bora Group”; TWSE: 6472; OTCQX: BORAY) today completed the re-election of its Board of Directors, with 7 Directors elected in total, including 4 Independent Directors. The Board includes 2 female members, and Independent Directors account for more than 1/3 of the seats, reinforcing the Company’s commitment to governance independence and diversity.
Newly elected Independent Director Dr. Leroy Yau, FCPA, is a former Big Four consulting partner with over 30 years of experience across Asia in governance, operations, and risk oversight across regulated industries. He currently serves as Chief of Staff at Anivia Medical Holdings and holds advisory roles across technology and AI-driven ventures. The diversified backgrounds of Board members are expected to support the Group as it navigates key operational priorities in CDMO capability and capacity expansion, while further evaluating AI-related business opportunities and geopolitical risks.